800.277.1193
Phone
Yet Another Pharmaceutical Company in India Gets an FDA Warning Over Valsartan Impurities
This month, a fourth Indian drug company involved in the manufacture of valsartan and another angiotensin II receptor blockers (ARBs) received an FDA warning letter over NDEA and NDMA found in its products.
Yet Another Sartan Drug Recalled Due to Carcinogens
Aurobindo Pharma USA, Inc. has issued a voluntary recall of three of its sartan-based prescription medications after discovering trace amounts of a carcinogenic substance known as N-nitrosodiethylamine (NDEA). The recall, which the FDA announced on Dec. 31st, affects a total of 80 lots of Valsartan, Amlodipine Valsartan, and Valsartan HCTZ pills with expiration dates between May 2019 and March 2021.
A Third Sartan Drug is Found to Contain NDEA
For the second time in as many weeks, the Food and Drug Administration has notified physicians and patients that yet another sartan drug used to treat hypertension has been contaminated with a carcinogenic industrial chemical. The manufacturer of the drug has issued a voluntary recall for a single lot of the medication losartan (potassium hydrochlorothiazide), identified as JB8912.
More Contamination Discovered in Recalled Valsartan
Only a few months ago, government health authorities in Europe and the U.S. issued recalls for the blood pressure medication valsartan over concerns of the presence of a carcinogenic industrial chemical known as N-nitrosodimethylamine (NDMA).
Hidden Carcinogen in Common Blood Pressure Medications Casts More Doubts Over China's Drug Industry
Last month, the China-based Zhejiang Huahai Pharmaceutical Company informed the European Medicines Agency that one of their products used in the treatment of hypertension, known as valsartan, had been contaminated with a chemical known as N-nitrosodimethylamine (NDMA). This substance is a known carcinogen that is used by researchers to intentionally produce cancer in laboratory rats.